Bhagirathbhai Dholaria

(iStock image)
December 8, 2025

Interim data reported for multiple myeloma off-the-shelf CAR-T therapy  

Vanderbilt-Ingram Cancer Center accrued the most patients nationwide for the clinical trial for P-BCMA-ALLO1 – a chimeric antigen receptor T cell therapy (CAR-T) derived from healthy donors’ white blood cells.

By Tom Wilemon
(iStock)
October 4, 2024

‘Off-the-shelf’ CAR-T therapy shows promise for relapsed/refractory multiple myeloma 

The therapy, P-BCMA-ALL01, demonstrated a 91% overall response rate for the 23 patients participating in the phase 1 trial.

By Tom Wilemon
September 10, 2021

Novel immunotherapy shows robust response for multiple myeloma

Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.

By Tom Wilemon